By combining Inscripta’s whole-genome engineering technologies with Manus’ cell factory engineering platform, biomanufacturing expertise, and commercialization capabilities, the merged company is uniquely positioned to deliver commercial momentum and scaled profitability in next-generation industrial biotechnology.
“Industrial biotech is at a turning point and needs to demonstrate execution at scale,” Ajikumar “Aji” Parayil, Founder and CEO of Manus, said in a press statement. “This merger brings together two cutting-edge technology and scale-up platforms and an unmatched commercial capability to meet the growing demand for bioalternatives. We are building a future where scalable, sustainable, and commercially viable bioalternatives become the solution.”
The combination aligns complementary product portfolios across food ingredients, beauty and wellness, and agricultural chemicals, while leveraging strong commercial traction. It is also supported by established strategic partnerships such as Manus’ new alliance with Tate & Lyle.
The merger has been approved by shareholders of both companies and is effective immediately.